TheStreet upgraded shares of Express Scripts (NASDAQ:ESRX) from a c+ rating to a b- rating in a research note published on Monday morning.

Several other brokerages also recently commented on ESRX. ValuEngine upgraded Express Scripts from a hold rating to a buy rating in a report on Monday. Deutsche Bank assumed coverage on shares of Express Scripts in a research note on Monday. They issued a buy rating and a $75.00 price objective on the stock. Robert W. Baird restated a hold rating and issued a $56.00 price objective on shares of Express Scripts in a research note on Friday, September 1st. Raymond James Financial restated an underperform rating on shares of Express Scripts in a research note on Monday, October 9th. Finally, UBS downgraded shares of Express Scripts from a market perform rating to an underperform rating in a research note on Monday, October 9th. Six equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Express Scripts presently has a consensus rating of Hold and a consensus price target of $70.67.

Shares of Express Scripts (NASDAQ ESRX) traded down $0.32 on Monday, reaching $67.84. 5,133,800 shares of the company traded hands, compared to its average volume of 4,121,163. Express Scripts has a 52-week low of $55.80 and a 52-week high of $77.25. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.61 and a current ratio of 0.73. The company has a market capitalization of $38,603.98, a price-to-earnings ratio of 9.96, a PEG ratio of 1.01 and a beta of 0.88.

Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.90 EPS for the quarter, meeting the consensus estimate of $1.90. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. The company had revenue of $24.68 billion for the quarter, compared to the consensus estimate of $25.68 billion. During the same quarter last year, the company posted $1.74 earnings per share. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. research analysts expect that Express Scripts will post 7.01 EPS for the current year.

In related news, Director Woodrow A. Myers, Jr. sold 3,900 shares of Express Scripts stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $63.93, for a total value of $249,327.00. Following the completion of the transaction, the director now directly owns 11,500 shares of the company’s stock, valued at $735,195. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Phyllis S. Anderson sold 643 shares of Express Scripts stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $62.37, for a total value of $40,103.91. The disclosure for this sale can be found here. Insiders sold 5,121 shares of company stock valued at $325,920 over the last ninety days. 0.68% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in ESRX. Nordea Investment Management AB increased its position in Express Scripts by 1.4% in the second quarter. Nordea Investment Management AB now owns 7,116,445 shares of the company’s stock worth $454,314,000 after purchasing an additional 97,953 shares during the period. First Trust Advisors LP grew its position in shares of Express Scripts by 25.3% during the 2nd quarter. First Trust Advisors LP now owns 708,955 shares of the company’s stock worth $45,260,000 after buying an additional 143,163 shares during the period. Van ECK Associates Corp grew its position in shares of Express Scripts by 5.1% during the 3rd quarter. Van ECK Associates Corp now owns 506,511 shares of the company’s stock worth $32,072,000 after buying an additional 24,728 shares during the period. Lazard Asset Management LLC grew its position in shares of Express Scripts by 81.8% during the 2nd quarter. Lazard Asset Management LLC now owns 112,666 shares of the company’s stock worth $7,192,000 after buying an additional 50,707 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Express Scripts by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 3,654,765 shares of the company’s stock worth $233,323,000 after buying an additional 62,263 shares during the period. 88.44% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Express Scripts (ESRX) Upgraded by TheStreet to “B-“” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/06/express-scripts-esrx-upgraded-by-thestreet-to-b.html.

About Express Scripts

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Stock Ratings for Express Scripts Holding Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts Holding Company and related stocks with our FREE daily email newsletter.